Feature | June 16, 2014

SCAI Publishes Expert Recommendations for Most Common Form of Peripheral Artery Disease

Second in appropriate use series provides guidance on treatment for blocked arteries above the knee

June 16, 2014 — New appropriate use expert consensus documents developed by the Society for Cardiovascular Angiography and Interventions (SCAI) provide guidance on treating the most common form of peripheral artery disease (PAD), namely blockages that affect arteries above the knee. The paper e-published in Catheterization & Cardiovascular Interventions is the second in a series of PAD treatment recommendations released by SCAI. The series is aimed at helping physicians determine treatment options for the growing number of patients impacted by PAD.

The newly published criteria address PAD in the femoropopliteal (FP) segment, the most common location of the disease. While most people with FP disease are asymptomatic, some patients whose severe blockages markedly reduced blood flow experience impaired walking, a condition known as intermittent claudication. Patients with more extensive blockages may develop critical limb ischemia in which the limb is threatened and may need amputation. These patients classically have blockages both above and below the knee. Patients with long-standing diabetes and/or chronic kidney disease and the elderly are most at risk of developing such blockages. As the population ages and number of patients with diabetes rises, the rate of critical limb ischemia is expected to grow.

“Our goal in treating patients with femoropopliteal disease is to reduce pain, improve walking ability and enhance quality of life,” said Douglas E. Drachman, M.D., FSCAI, director of the Cardiology Fellowship Program at Massachusetts General Hospital and senior author of the consensus paper. “As technology has advanced, there are now safe and effective endovascular treatment options for a range of patients, not just those at high surgical risk.”

An expert panel developed the new recommendations by reviewing scientific data available on each treatment option. The panel found that balloon angioplasty continues to be a valid treatment, but with suboptimal long-term results in patients with long blockages, critical limb ischemia, diabetes or areas of complete blockage. The paper discusses use of self-expanding stents, covered stents and non-stenting alternatives, including atherectomy, in which obstruction is relieved by extracting arterial plaque.

The expert consensus document is the second in SCAI’s series of appropriate use recommendations for treating PAD. The earlier document, “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Aorto-Iliac Arterial Intervention,” was published in May 2014.  Forthcoming publications, addressing infrapopliteal PAD and renal artery stenosis, will be published in Catheterization & Cardiovascular Interventions later this summer.

“As the incidence of PAD grows, SCAI is committed to helping physicians provide the best treatment options for the patient’s own condition and treatment goals,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “We want to help physicians find the safest treatment option that provides the greatest relief and improves quality of life.”

The paper, titled “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Femoral-Popliteal Arterial Intervention,” is published in Catheterization & Cardiovascular Interventions.

For more information: www.scai.org

Related Content

he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic...
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded tria
The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the U
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-elutin
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...